Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBITDA (2016 - 2026)

Collegium Pharmaceutical has reported EBITDA over the past 10 years, most recently at $60.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 59.42% year-over-year to $60.8 million; the TTM value through Dec 2025 reached $179.6 million, up 5.73%, while the annual FY2025 figure was $183.8 million, 5.79% up from the prior year.
  • EBITDA for Q4 2025 was $60.8 million at Collegium Pharmaceutical, down from $62.1 million in the prior quarter.
  • Over five years, EBITDA peaked at $62.1 million in Q3 2025 and troughed at -$34.1 million in Q4 2021.
  • A 5-year average of $28.4 million and a median of $29.7 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 327.54% in 2021 and later surged 424.69% in 2023.
  • Year by year, EBITDA stood at -$34.1 million in 2021, then soared by 134.46% to $11.8 million in 2022, then surged by 424.69% to $61.7 million in 2023, then tumbled by 38.22% to $38.1 million in 2024, then skyrocketed by 59.42% to $60.8 million in 2025.
  • Business Quant data shows EBITDA for COLL at $60.8 million in Q4 2025, $62.1 million in Q3 2025, and $35.1 million in Q2 2025.